Neuropsychiatric symptoms in cognitive decline and Alzheimer’s disease: biomarker discovery using plasma proteomics

Authors

Loı̈c Dayon (ORCID: https://orcid.org/0000-0002-8499-270X)
Julius Popp (ORCID: https://orcid.org/0000-0002-0068-0312)
Miriam Rabl (ORCID: https://orcid.org/0000-0002-3189-6554)
Christopher Clark

Institutions

University of Zurich (CH)
University Hospital of Zurich (CH)
Nestlé (Switzerland) (CH)
University Psychiatric Hospital (SI)
École Polytechnique Fédérale de Lausanne (CH)
University of Lausanne (CH)

Publication Details

Journal: Journal of Neurology Neurosurgery & Psychiatry
Published: 2024-09-17
DOI: https://doi.org/10.1136/jnnp-2024-333819
Citations: 14
Primary Topic: Alzheimer's disease research and treatments
Type: article
Field-Weighted Citation Impact: 4.57

Funders

Foundation for the National Institutes of Health
Alzheimer's Association
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
Merck
Biogen
AbbVie
Meso Scale Diagnostics
BioClinica
Novartis Pharmaceuticals Corporation
Takeda Pharmaceutical Company
Northern California Institute for Research and Education
Fujirebio US
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Lundbeckfonden
Universität Zürich
Stiftung Synapsis - Alzheimer Forschung Schweiz AFS
Servier
IXICO
Genentech
GE Healthcare
Defense Health Agency
Canadian Institutes of Health Research
Eisai Incorporated
NIH Clinical Center
Janssen Pharmaceuticals
Johnson and Johnson Pharmaceutical Research and Development

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Neuropsychiatric symptoms in cognitive decline and Alzheimer’s disease: biomarker discovery using plasma proteomics

Loı̈c Dayon, Julius Popp, Miriam Rabl, Christopher Clark

Sep 17, 2024

14 citations

Journal of Neurology Neurosurgery & Psychiatry

Alzheimer's disease research and treatments

4.57

article

Neuropsychiatric symptoms in cognitive decline and Alzheimer’s disease: biomarker discovery using plasma proteomics

Loı̈c Dayon, Julius Popp, Miriam Rabl, Christopher Clark

September 17, 2024article en

14 citations

Abstract

No abstract available for this paper.

Journal of Neurology Neurosurgery & PsychiatryVol. 96(4)

University of Zurich (CH), University Hospital of Zurich (CH), Nestlé (Switzerland) (CH), University Psychiatric Hospital (SI), École Polytechnique Fédérale de Lausanne (CH), University of Lausanne (CH)

Foundation for the National Institutes of Health, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Merck, Biogen, AbbVie, Meso Scale Diagnostics, BioClinica, Novartis Pharmaceuticals Corporation, Takeda Pharmaceutical Company, Northern California Institute for Research and Education, Fujirebio US, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Lundbeckfonden, Universität Zürich, Stiftung Synapsis - Alzheimer Forschung Schweiz AFS, Servier, IXICO, Genentech, GE Healthcare, Defense Health Agency, Canadian Institutes of Health Research, Eisai Incorporated, NIH Clinical Center, Janssen Pharmaceuticals, Johnson and Johnson Pharmaceutical Research and Development

Good health and well-being

Openalex Percentile: Top 4%

Alzheimer's disease research and treatments

4.57

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.